AI cardiovascular imaging company HeartFlow has filed a patent infringement lawsuit against its competitor Cleerly seeking permanent injunctive relief and damages.
The lawsuit, filed April 13 in the U.S. District Court for the Eastern District of Texas, alleges that Cleerly's Ischemia, Plaque Analysis, and Compare products infringe one or more claims of the following six HeartFlow U.S. patents:
- Patent no. 11,288,813, issued on March 29, 2022, and titled “Systems and methods for anatomic structure segmentation in image analysis.”
- Patent no. 11,382,569, issued on July 12, 2022, and titled “Systems and methods for estimating blood flow characteristics from vessel geometry and physiology.”
- Patent no. 9,770,303, issued on September 26, 2017, and titled “Systems and methods for predicting coronary plaque vulnerability from patient-specific anatomic image data.”
- Patent no. 9,839,399, issued on December 12, 2017, and titled “Systems and Methods for Numerically Evaluating Vasculature.”
- Patent no. 9,607,386, issued on March 28, 2017, and titled “Systems and methods for correction of artificial deformation in anatomic modeling.”
- Patent no. 11,013,425, issued on May 25, 2021, and titled “Systems and methods for analyzing and processing digital images to estimate vessel characteristics.”
Cleerly founder James K. Min, MD, served as a consultant to HeartFlow from 2012 to 2017, the complaint explained. In a statement via email, Min said, "we are confident in our extensive and well-established intellectual property portfolio and the originality of our technology."
HeartFlow has demanded a jury trial.
